Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II/III double-blind study of BAT4406F injection in neuromyelitis optica spectrum disorder
CTR20231610Phase 3Active
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Jul 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of BAT4406F in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by Bio-Thera Solutions, Ltd.. Started Jul 2023; status: active.
02
Drugs
BAT4406F
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on CTR20231610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231610.